董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James F. Oliviero, III | 男 | Chief Executive Officer, President and Director | 47 | 204.22万美元 | 未持股 | 2023-05-01 |
| Barry Salzman | 男 | Director | 61 | 10.00万美元 | 未持股 | 2023-05-01 |
| Scott Boilen | 男 | Director | 56 | 10.00万美元 | 未持股 | 2023-05-01 |
| Lindsay A. Rosenwald | 男 | Director | 68 | 10.00万美元 | 未持股 | 2023-05-01 |
| Christian Bechon | 男 | Director | 63 | 未披露 | 未持股 | 2023-05-01 |
| Michael S. Weiss | 男 | Chairman of the Board | 57 | 11.00万美元 | 未持股 | 2023-05-01 |
| Neil Herskowitz | 男 | Director | 66 | 11.00万美元 | 未持股 | 2023-05-01 |
| Christian Bechon | 男 | Director | 63 | 10.00万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James F. Oliviero, III | 男 | Chief Executive Officer, President and Director | 47 | 204.22万美元 | 未持股 | 2023-05-01 |
| Garrett Gray | 男 | Chief Financial Officer, Corporate Secretary and Treasurer | 35 | 71.24万美元 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- James F. Oliviero, III
-
JamesF.Oliviero，III自2015年10月13日以来一直担任我们的首席执行官兼总裁。Oliviero先生在生物技术行业拥有超过15年的运营经验。从2003年5月到2015年9月，Oliviero先生在KeryxBiopharmaceuticals，Inc.担任过各种领导职务，该公司是一家公开上市的生物技术公司，最近自2009年4月以来担任其首席财务官，他在该公司成长为市值超过10亿美元的公司中发挥了重要作用。在Keryx任职期间，Oliviero先生监督所有财务，会计，投资者关系，公司治理，业务发展和法律事务，以及几个临床研究的设计和Keryx’；的新药Auryxia™的监管监督的领导成员；于2014年成功获得FDA上市批准，并于最近获得EMA上市批准。在Keryx任职期间，Oliviero先生为该公司完成了超过5亿美元的各种公共融资。任职Keryx公司之前，Oliviero从1999年8月到2003年5月担任Access Oncology，Inc.（一家私人生物技术公司）金融主管。Oliviero先生的职业生涯始于担任纽约市ING Barings Furman Selz的投资银行家。Oliviero先生是CFA特许持有人，并拥有埃默里大学戈伊祖埃塔商学院（Emory University’；S Goizueta Business School）最高荣誉的金融学学士学位。
James F. Oliviero, III has been Checkpoint Therapeutics, Inc. Chief Executive Officer and President since October 13 2015. Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015 Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc., a publicly-traded biotechnology company, most recently as its Chief Financial Officer since April 2009 where he was instrumental in the growth of the company to a market capitalization over $1 billion. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx's new drug application for Auryxia, which successfully obtained FDA marketing approval in 2014 and recently gained EMA marketing approval. Also while at Keryx, Mr. Oliviero completed over $500 million in various public financings for the company. Prior to Keryx, from August 1999 to May 2003 Mr. Oliviero was Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. Mr. Oliviero began his professional career as an investment banker at ING Barings Furman Selz in New York City. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School. - JamesF.Oliviero，III自2015年10月13日以来一直担任我们的首席执行官兼总裁。Oliviero先生在生物技术行业拥有超过15年的运营经验。从2003年5月到2015年9月，Oliviero先生在KeryxBiopharmaceuticals，Inc.担任过各种领导职务，该公司是一家公开上市的生物技术公司，最近自2009年4月以来担任其首席财务官，他在该公司成长为市值超过10亿美元的公司中发挥了重要作用。在Keryx任职期间，Oliviero先生监督所有财务，会计，投资者关系，公司治理，业务发展和法律事务，以及几个临床研究的设计和Keryx’；的新药Auryxia™的监管监督的领导成员；于2014年成功获得FDA上市批准，并于最近获得EMA上市批准。在Keryx任职期间，Oliviero先生为该公司完成了超过5亿美元的各种公共融资。任职Keryx公司之前，Oliviero从1999年8月到2003年5月担任Access Oncology，Inc.（一家私人生物技术公司）金融主管。Oliviero先生的职业生涯始于担任纽约市ING Barings Furman Selz的投资银行家。Oliviero先生是CFA特许持有人，并拥有埃默里大学戈伊祖埃塔商学院（Emory University’；S Goizueta Business School）最高荣誉的金融学学士学位。
- James F. Oliviero, III has been Checkpoint Therapeutics, Inc. Chief Executive Officer and President since October 13 2015. Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015 Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc., a publicly-traded biotechnology company, most recently as its Chief Financial Officer since April 2009 where he was instrumental in the growth of the company to a market capitalization over $1 billion. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx's new drug application for Auryxia, which successfully obtained FDA marketing approval in 2014 and recently gained EMA marketing approval. Also while at Keryx, Mr. Oliviero completed over $500 million in various public financings for the company. Prior to Keryx, from August 1999 to May 2003 Mr. Oliviero was Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. Mr. Oliviero began his professional career as an investment banker at ING Barings Furman Selz in New York City. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School.
- Barry Salzman
-
Barry Salzman于2016年1月加入我们的董事会。Salzman先生目前是Compass Partners LLC的常务董事，该公司是一家商业银行和金融咨询公司，专门从事中间市场公司和企业重组。Salzman先生于2007年7月加入Compass Partners LLC，同时成为BP Gamma Medical Supply Company的董事会成员和主要所有者。在2007年7月之前，Salzman先生担任Becker-Parkin Dental Supply Company的董事会主席，总裁兼主要所有者。在Becker-Parkin任职20年后，Salzman先生将公司出售给Henry Schein Inc.。纳斯达克股票代码:HSIC。出售Becker-Parkin五个月后，Salzman先生担任Surgery Works，LLC的总裁，该公司由Compass Partners LLC成立，为流动手术中心提供财务管理服务，直到该中心将控股权出售给AmSurg（NASDAQ:AMSG）。Salzman先生一直在两个Surgery Works，LLC Centers保持董事会席位，并继续担任AmSurg的咨询和顾问职位。Salzman先生于2014年创立并成为Practice Management Works LLC的总裁，并接受了Vivex Corporation的董事会席位，该公司是一家私人研究驱动型生物制剂公司。Salzman先生1987年毕业于布鲁克林法学院（Brooklyn Law School），是纽约律师协会（New York Bar Association）信誉良好的会员。
Barry Salzman joined Checkpoint Therapeutics, Inc. Board of Directors in January 2016. Mr. Salzman is currently a Managing Director for Compass Partners LLC, a merchant banking and financial advisory firm that specializes in middle market companies and corporate restructuring. Mr. Salzman joined Compass Partners LLC in July 2007 the same time at which he became a Board Member and Principal owner of BP Gamma Medical Supply Company. Prior to July 2007 Mr. Salzman served as Board Chairman, President and Principal owner of Becker-Parkin Dental Supply Company. After 20 years at Becker-Parkin, Mr. Salzman sold the company to Henry Schein Inc. NASDAQ: HSIC. Five months after selling Becker-Parkin, Mr. Salzman served as President of Surgery Works, LLC, formed by Compass Partners LLC to provide financial management services for Ambulatory Surgery Centers until the centers sold a controlling interest to Amsurg (NASDAQ: AMSG). Mr. Salzman has maintained a Board seat at both Surgery Works, LLC centers and continues to work in a consulting and advisory role to Amsurg. In 2014 Mr. Salzman founded and became President of Practice Management Works LLC and also accepted a board seat at Vivex Corporation, a private research driven Biologicals Company. Mr. Salzman is a 1987 graduate of Brooklyn Law School and is a member in good standing of the New York Bar Association. - Barry Salzman于2016年1月加入我们的董事会。Salzman先生目前是Compass Partners LLC的常务董事，该公司是一家商业银行和金融咨询公司，专门从事中间市场公司和企业重组。Salzman先生于2007年7月加入Compass Partners LLC，同时成为BP Gamma Medical Supply Company的董事会成员和主要所有者。在2007年7月之前，Salzman先生担任Becker-Parkin Dental Supply Company的董事会主席，总裁兼主要所有者。在Becker-Parkin任职20年后，Salzman先生将公司出售给Henry Schein Inc.。纳斯达克股票代码:HSIC。出售Becker-Parkin五个月后，Salzman先生担任Surgery Works，LLC的总裁，该公司由Compass Partners LLC成立，为流动手术中心提供财务管理服务，直到该中心将控股权出售给AmSurg（NASDAQ:AMSG）。Salzman先生一直在两个Surgery Works，LLC Centers保持董事会席位，并继续担任AmSurg的咨询和顾问职位。Salzman先生于2014年创立并成为Practice Management Works LLC的总裁，并接受了Vivex Corporation的董事会席位，该公司是一家私人研究驱动型生物制剂公司。Salzman先生1987年毕业于布鲁克林法学院（Brooklyn Law School），是纽约律师协会（New York Bar Association）信誉良好的会员。
- Barry Salzman joined Checkpoint Therapeutics, Inc. Board of Directors in January 2016. Mr. Salzman is currently a Managing Director for Compass Partners LLC, a merchant banking and financial advisory firm that specializes in middle market companies and corporate restructuring. Mr. Salzman joined Compass Partners LLC in July 2007 the same time at which he became a Board Member and Principal owner of BP Gamma Medical Supply Company. Prior to July 2007 Mr. Salzman served as Board Chairman, President and Principal owner of Becker-Parkin Dental Supply Company. After 20 years at Becker-Parkin, Mr. Salzman sold the company to Henry Schein Inc. NASDAQ: HSIC. Five months after selling Becker-Parkin, Mr. Salzman served as President of Surgery Works, LLC, formed by Compass Partners LLC to provide financial management services for Ambulatory Surgery Centers until the centers sold a controlling interest to Amsurg (NASDAQ: AMSG). Mr. Salzman has maintained a Board seat at both Surgery Works, LLC centers and continues to work in a consulting and advisory role to Amsurg. In 2014 Mr. Salzman founded and became President of Practice Management Works LLC and also accepted a board seat at Vivex Corporation, a private research driven Biologicals Company. Mr. Salzman is a 1987 graduate of Brooklyn Law School and is a member in good standing of the New York Bar Association.
- Scott Boilen
-
Scott Boilen于2016年4月加入我们的董事会。Boilen先生自1999年以来担任Allstar Products Group的首席执行官。他也曾任职the Electronic Retailing Association的董事会（从2010年到2012年），以及the Food Bank for Westchester New York的董事会（2009年以来）。Boilen持有the State University of New York at Albany工商管理学位，以及Fordham University工商管理硕士学位。
Scott Boilen joined Checkpoint Therapeutics, Inc. Board of Directors in April 2016. Mr. Boilen has served as the Chief Executive Officer of Allstar Products Group since 1999. He also served on the Board of Directors for the Electronic Retailing Association from 2010 to 2012 and the Board of Directors for the Food Bank for Westchester New York since 2009. Boilen holds a degree in Business Administration from the State University of New York at Albany and a Master's Degree in Business Administration from Fordham University. - Scott Boilen于2016年4月加入我们的董事会。Boilen先生自1999年以来担任Allstar Products Group的首席执行官。他也曾任职the Electronic Retailing Association的董事会（从2010年到2012年），以及the Food Bank for Westchester New York的董事会（2009年以来）。Boilen持有the State University of New York at Albany工商管理学位，以及Fordham University工商管理硕士学位。
- Scott Boilen joined Checkpoint Therapeutics, Inc. Board of Directors in April 2016. Mr. Boilen has served as the Chief Executive Officer of Allstar Products Group since 1999. He also served on the Board of Directors for the Electronic Retailing Association from 2010 to 2012 and the Board of Directors for the Food Bank for Westchester New York since 2009. Boilen holds a degree in Business Administration from the State University of New York at Albany and a Master's Degree in Business Administration from Fordham University.
- Lindsay A. Rosenwald
-
Lindsay A. Rosenwald， 他是医学博士，曾担任董事会成员（2009年10月以来），也曾担任董事长、总裁兼首席执行官（2013年12月以来）。他目前担任 Opus Point Partners（资产管理公司在生命科学行业）的合伙经理人和合伙人（始于2009年）。从1991年到2008年，他担任Paramount BioCapital的主席。在过去的23年，他曾任职众多上市和私人的资本重组的生物技术和生命科学公司，一直担任生物技术博士和企业家。他获得到宾夕法尼亚州立大学金融学士学位和Temple University医学院的医学博士学位。
Lindsay A. Rosenwald has served as a member of Mtang Bio, Inc. Board since Mtang Bio, Inc. inception. Dr. Rosenwald has been a member of the board of directors of Fortress Biotech, Inc. since October 2009 and has served as its Chairman, President and Chief Executive Officer since December 2013. From November 2014 to Augt 2015, Dr. Rosenwald served as Interim President and CEO of Checkpoint Therapeutics, Inc. and remained on that company's board of directors until its acquisition by Sun Pharmaceuticals in May 2025. He also serves on the board of directors of Avenue Therapeutics, Inc. and Jney Medical Corporation. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 30 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numero public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine. - Lindsay A. Rosenwald， 他是医学博士，曾担任董事会成员（2009年10月以来），也曾担任董事长、总裁兼首席执行官（2013年12月以来）。他目前担任 Opus Point Partners（资产管理公司在生命科学行业）的合伙经理人和合伙人（始于2009年）。从1991年到2008年，他担任Paramount BioCapital的主席。在过去的23年，他曾任职众多上市和私人的资本重组的生物技术和生命科学公司，一直担任生物技术博士和企业家。他获得到宾夕法尼亚州立大学金融学士学位和Temple University医学院的医学博士学位。
- Lindsay A. Rosenwald has served as a member of Mtang Bio, Inc. Board since Mtang Bio, Inc. inception. Dr. Rosenwald has been a member of the board of directors of Fortress Biotech, Inc. since October 2009 and has served as its Chairman, President and Chief Executive Officer since December 2013. From November 2014 to Augt 2015, Dr. Rosenwald served as Interim President and CEO of Checkpoint Therapeutics, Inc. and remained on that company's board of directors until its acquisition by Sun Pharmaceuticals in May 2025. He also serves on the board of directors of Avenue Therapeutics, Inc. and Jney Medical Corporation. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 30 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numero public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine.
- Christian Bechon
-
Christian Bechon，于2018年10月加入↓ Checkpoint Therapeutics，Inc. Checkpoint医疗公司董事会。他目前是私人控股的生命科学咨询公司ChB Consultants的董事长兼首席执行官。2006年至2017年，B é chon先生担任法国生物制药公司LFB S.A.的董事长兼首席执行官，该公司年收入超过5亿欧元。此前，他曾于2005年和2006年担任波士顿咨询公司的高级顾问。在他职业生涯的早期，他曾在法国政府担任过多个职位，包括公共卫生和健康保险部长的参谋长。2000年至2004年，他担任副总参谋长至经济、财政和工业部长。他毕业于Ecole Centrale des Arts et Manufactures工程学院、Institut d‘Etudes Politiques de Paris和Ecole Nationale d’Administration。B é chon先生是Quantum Genomics（ALQGC）董事会成员，曾是美国、墨西哥和欧洲私营公司的董事会成员。他获得了无数奖项和勋章，包括法国荣誉军团骑士勋章和法国国家功勋勋章。
Christian Bechon,joined Checkpoint Therapeutics, Inc. Board of Directors in October 2018. He is currently Chairman and Chief Executive Officer of ChB Consultants, a privately held life science consultancy company. From 2006 to 2017, Mr. Béchon was Chairman and Chief Executive Officer of LFB S.A., a French biopharmaceutical company with more than 500M in annual revenue. Previously, he was Senior Advisor for the Boston Consulting Group in 2005 and 2006. Earlier in his career, he held various positions in the French government, including Chief of Staff to the Minister for Public Health and Health Insurance. From 2000 to 2004, he was Deputy Chief of Staff to the Minister of the Economy, Finance and Industry. He is a graduate of the Ecole Centrale des Arts et Manufactures engineering school, Institut d'Etudes Politiques de Paris and Ecole Nationale d'Administration. Mr. Béchon is a member of Quantum Genomics' (ALQGC) Board of Directors and has been a Board member of private companies in the USA, Mexico and Europe. He has received numerous awards and medals, including the Knight of the French Legion of Honor and the French National Order of Merit. - Christian Bechon，于2018年10月加入↓ Checkpoint Therapeutics，Inc. Checkpoint医疗公司董事会。他目前是私人控股的生命科学咨询公司ChB Consultants的董事长兼首席执行官。2006年至2017年，B é chon先生担任法国生物制药公司LFB S.A.的董事长兼首席执行官，该公司年收入超过5亿欧元。此前，他曾于2005年和2006年担任波士顿咨询公司的高级顾问。在他职业生涯的早期，他曾在法国政府担任过多个职位，包括公共卫生和健康保险部长的参谋长。2000年至2004年，他担任副总参谋长至经济、财政和工业部长。他毕业于Ecole Centrale des Arts et Manufactures工程学院、Institut d‘Etudes Politiques de Paris和Ecole Nationale d’Administration。B é chon先生是Quantum Genomics（ALQGC）董事会成员，曾是美国、墨西哥和欧洲私营公司的董事会成员。他获得了无数奖项和勋章，包括法国荣誉军团骑士勋章和法国国家功勋勋章。
- Christian Bechon,joined Checkpoint Therapeutics, Inc. Board of Directors in October 2018. He is currently Chairman and Chief Executive Officer of ChB Consultants, a privately held life science consultancy company. From 2006 to 2017, Mr. Béchon was Chairman and Chief Executive Officer of LFB S.A., a French biopharmaceutical company with more than 500M in annual revenue. Previously, he was Senior Advisor for the Boston Consulting Group in 2005 and 2006. Earlier in his career, he held various positions in the French government, including Chief of Staff to the Minister for Public Health and Health Insurance. From 2000 to 2004, he was Deputy Chief of Staff to the Minister of the Economy, Finance and Industry. He is a graduate of the Ecole Centrale des Arts et Manufactures engineering school, Institut d'Etudes Politiques de Paris and Ecole Nationale d'Administration. Mr. Béchon is a member of Quantum Genomics' (ALQGC) Board of Directors and has been a Board member of private companies in the USA, Mexico and Europe. He has received numerous awards and medals, including the Knight of the French Legion of Honor and the French National Order of Merit.
- Michael S. Weiss
-
Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019. - Michael S. Weiss，2011年12月起担任TG的执行主席、临时首席执行官和总裁。他是Opus Point Partners的联合创始人，2008年起担任起管理合伙人和主席。他获有Columbia Law School的法律博士学位，以及The University at Albany的金融学学士学位。他的职业生涯起始于在Cravath, Swaine & Moore担任律师。1999年，他创立Access Oncology，该公司2004年被Keryx Biopharmaceuticals （NASDAQ： KERX）收购。此后，他仍旧担任Keryx的首席执行官，带领公司在顶峰时达到10亿美元市值。在Keryx期间，通过上市和私募发行，他筹集过1.5亿美元的权益资本；执行过1亿美元的战略联盟，与FDA谈判过众多特殊方案评价，管理过多家大型临床试验公司。
- Michael S. Weiss has served as Chairman of Mtang Bio, Inc. Board since May 2015 and has also served as Mtang Bio, Inc. Executive Chairman since January 2017. He previoly served as Mtang Bio, Inc. interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014, and previoly served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc., prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. iss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. iss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. iss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. iss co founded and served as Co Portfolio Manager and Managing Partner of Op Point Partners, LLC from 2009 to 2019.
- Neil Herskowitz
-
Neil Herskowitz，2004年7月在董事会任职。2004年起，他是位于纽约的投资基金ReGen Partners LLC的管理成员，也是其分公司Riverside Claims LLC的总裁。此前，他担任上市医药发展公司Chelsea Therapeutics CHTP董事和审计委员会主席。他也是非盈利机构Starting Point Services for Children的董事成员。他1978年获得Bernard M. Baruch College金融学学士学位。
Neil Herskowitz has served as a member of Mtang Bio, Inc. Board since Augt 2015. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004. Mr. Herskowitz serves as a member of the board of directors for two of affiliates, Checkpoint Therapeutics, Inc. and Avenue Therapeutics, Inc. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978. - Neil Herskowitz，2004年7月在董事会任职。2004年起，他是位于纽约的投资基金ReGen Partners LLC的管理成员，也是其分公司Riverside Claims LLC的总裁。此前，他担任上市医药发展公司Chelsea Therapeutics CHTP董事和审计委员会主席。他也是非盈利机构Starting Point Services for Children的董事成员。他1978年获得Bernard M. Baruch College金融学学士学位。
- Neil Herskowitz has served as a member of Mtang Bio, Inc. Board since Augt 2015. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004. Mr. Herskowitz serves as a member of the board of directors for two of affiliates, Checkpoint Therapeutics, Inc. and Avenue Therapeutics, Inc. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978.
- Christian Bechon
-
Christian Bechon自2006年以来一直担任我们的董事会成员，在此期间，Bechon先生还担任LFB的董事长兼首席执行官。2005年，Bechon先生担任波士顿咨询集团（Boston Consulting Group）的高级顾问。从2002年到2004年，Bechon先生担任法国总理让-皮埃尔·拉法兰（Jean-Pierre Raffarin）领导下的经济、财政与工业部的副参谋长。Bechon先生拥有巴黎政治学院（Institut D’；Etudes Politiques de Paris）的工程学位。
Christian Bechon has served as a member of rEVO Biologics, Inc. board of directors since 2006 during which time Mr. Bechon has also served as the chairman and chief executive officer of LFB. In 2005 Mr. Bechon served as a senior advisor for the Boston Consulting Group. From 2002 to 2004 Mr. Bechon served as the deputy chief of staff at the Ministry of the Economy, Finance and Industry under French Prime Minister Jean-Pierre Raffarin. Mr. Bechon holds a degree in engineering from the Ecole Centrale des Arts et Manufactures, Institut d'Etudes Politiques de Paris. - Christian Bechon自2006年以来一直担任我们的董事会成员，在此期间，Bechon先生还担任LFB的董事长兼首席执行官。2005年，Bechon先生担任波士顿咨询集团（Boston Consulting Group）的高级顾问。从2002年到2004年，Bechon先生担任法国总理让-皮埃尔·拉法兰（Jean-Pierre Raffarin）领导下的经济、财政与工业部的副参谋长。Bechon先生拥有巴黎政治学院（Institut D’；Etudes Politiques de Paris）的工程学位。
- Christian Bechon has served as a member of rEVO Biologics, Inc. board of directors since 2006 during which time Mr. Bechon has also served as the chairman and chief executive officer of LFB. In 2005 Mr. Bechon served as a senior advisor for the Boston Consulting Group. From 2002 to 2004 Mr. Bechon served as the deputy chief of staff at the Ministry of the Economy, Finance and Industry under French Prime Minister Jean-Pierre Raffarin. Mr. Bechon holds a degree in engineering from the Ecole Centrale des Arts et Manufactures, Institut d'Etudes Politiques de Paris.
高管简历
中英对照 | 中文 | 英文- James F. Oliviero, III
JamesF.Oliviero，III自2015年10月13日以来一直担任我们的首席执行官兼总裁。Oliviero先生在生物技术行业拥有超过15年的运营经验。从2003年5月到2015年9月，Oliviero先生在KeryxBiopharmaceuticals，Inc.担任过各种领导职务，该公司是一家公开上市的生物技术公司，最近自2009年4月以来担任其首席财务官，他在该公司成长为市值超过10亿美元的公司中发挥了重要作用。在Keryx任职期间，Oliviero先生监督所有财务，会计，投资者关系，公司治理，业务发展和法律事务，以及几个临床研究的设计和Keryx’；的新药Auryxia™的监管监督的领导成员；于2014年成功获得FDA上市批准，并于最近获得EMA上市批准。在Keryx任职期间，Oliviero先生为该公司完成了超过5亿美元的各种公共融资。任职Keryx公司之前，Oliviero从1999年8月到2003年5月担任Access Oncology，Inc.（一家私人生物技术公司）金融主管。Oliviero先生的职业生涯始于担任纽约市ING Barings Furman Selz的投资银行家。Oliviero先生是CFA特许持有人，并拥有埃默里大学戈伊祖埃塔商学院（Emory University’；S Goizueta Business School）最高荣誉的金融学学士学位。
James F. Oliviero, III has been Checkpoint Therapeutics, Inc. Chief Executive Officer and President since October 13 2015. Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015 Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc., a publicly-traded biotechnology company, most recently as its Chief Financial Officer since April 2009 where he was instrumental in the growth of the company to a market capitalization over $1 billion. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx's new drug application for Auryxia, which successfully obtained FDA marketing approval in 2014 and recently gained EMA marketing approval. Also while at Keryx, Mr. Oliviero completed over $500 million in various public financings for the company. Prior to Keryx, from August 1999 to May 2003 Mr. Oliviero was Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. Mr. Oliviero began his professional career as an investment banker at ING Barings Furman Selz in New York City. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School.- JamesF.Oliviero，III自2015年10月13日以来一直担任我们的首席执行官兼总裁。Oliviero先生在生物技术行业拥有超过15年的运营经验。从2003年5月到2015年9月，Oliviero先生在KeryxBiopharmaceuticals，Inc.担任过各种领导职务，该公司是一家公开上市的生物技术公司，最近自2009年4月以来担任其首席财务官，他在该公司成长为市值超过10亿美元的公司中发挥了重要作用。在Keryx任职期间，Oliviero先生监督所有财务，会计，投资者关系，公司治理，业务发展和法律事务，以及几个临床研究的设计和Keryx’；的新药Auryxia™的监管监督的领导成员；于2014年成功获得FDA上市批准，并于最近获得EMA上市批准。在Keryx任职期间，Oliviero先生为该公司完成了超过5亿美元的各种公共融资。任职Keryx公司之前，Oliviero从1999年8月到2003年5月担任Access Oncology，Inc.（一家私人生物技术公司）金融主管。Oliviero先生的职业生涯始于担任纽约市ING Barings Furman Selz的投资银行家。Oliviero先生是CFA特许持有人，并拥有埃默里大学戈伊祖埃塔商学院（Emory University’；S Goizueta Business School）最高荣誉的金融学学士学位。
- James F. Oliviero, III has been Checkpoint Therapeutics, Inc. Chief Executive Officer and President since October 13 2015. Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015 Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc., a publicly-traded biotechnology company, most recently as its Chief Financial Officer since April 2009 where he was instrumental in the growth of the company to a market capitalization over $1 billion. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx's new drug application for Auryxia, which successfully obtained FDA marketing approval in 2014 and recently gained EMA marketing approval. Also while at Keryx, Mr. Oliviero completed over $500 million in various public financings for the company. Prior to Keryx, from August 1999 to May 2003 Mr. Oliviero was Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. Mr. Oliviero began his professional career as an investment banker at ING Barings Furman Selz in New York City. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University's Goizueta Business School.
- Garrett Gray
Garrett Gray，自2020年12月起担任Checkpoint医疗公司首席财务官，自2016年12月起担任Checkpoint医疗公司首席财务官，自2018年1月起担任Checkpoint医疗公司公司秘书和财务主管。Gray先生于2016年2月至2020年12月担任Checkpoint医疗公司财务和会计副总裁。Gray先生于2013年从上市的生物技术公司Keryx Biopharmaceuticals, Inc.加入Checkpoint医疗，Inc.，他最近在该公司担任公司财务总监，在Keryx从一家发展阶段的公司过渡到一家完全集成的商业组织期间，帮助发展了财务和会计部门。在加入Keryx之前，Gray先生在Deloitte & Touche，LLP开始了他的职业生涯，在那里他担任高级审计师。Gray先生拥有利哈伊大学会计学理学学士学位，是纽约州的注册会计师。
Garrett Gray,has served as Checkpoint Therapeutics, Inc. Chief Financial Officer since December 2020, as Checkpoint Therapeutics, Inc. Principal Financial Officer since December 2016, and as Checkpoint Therapeutics, Inc. Corporate Secretary and Treasurer since January 2018. Mr. Gray served as Checkpoint Therapeutics, Inc. Vice President, Finance and Accounting from February 2016 until December 2020. Mr. Gray joined Checkpoint Therapeutics, Inc. from Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, which he joined in 2013, and where he most recently served as Corporate Controller, helping grow the finance and accounting department during Keryx's transition from a development-stage company to a fully integrated commercial organization. Prior to joining Keryx, Mr. Gray began his professional career with Deloitte & Touche, LLP, where he served as a senior auditor. Mr. Gray has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New York.- Garrett Gray，自2020年12月起担任Checkpoint医疗公司首席财务官，自2016年12月起担任Checkpoint医疗公司首席财务官，自2018年1月起担任Checkpoint医疗公司公司秘书和财务主管。Gray先生于2016年2月至2020年12月担任Checkpoint医疗公司财务和会计副总裁。Gray先生于2013年从上市的生物技术公司Keryx Biopharmaceuticals, Inc.加入Checkpoint医疗，Inc.，他最近在该公司担任公司财务总监，在Keryx从一家发展阶段的公司过渡到一家完全集成的商业组织期间，帮助发展了财务和会计部门。在加入Keryx之前，Gray先生在Deloitte & Touche，LLP开始了他的职业生涯，在那里他担任高级审计师。Gray先生拥有利哈伊大学会计学理学学士学位，是纽约州的注册会计师。
- Garrett Gray,has served as Checkpoint Therapeutics, Inc. Chief Financial Officer since December 2020, as Checkpoint Therapeutics, Inc. Principal Financial Officer since December 2016, and as Checkpoint Therapeutics, Inc. Corporate Secretary and Treasurer since January 2018. Mr. Gray served as Checkpoint Therapeutics, Inc. Vice President, Finance and Accounting from February 2016 until December 2020. Mr. Gray joined Checkpoint Therapeutics, Inc. from Keryx Biopharmaceuticals, Inc., a publicly traded biotechnology company, which he joined in 2013, and where he most recently served as Corporate Controller, helping grow the finance and accounting department during Keryx's transition from a development-stage company to a fully integrated commercial organization. Prior to joining Keryx, Mr. Gray began his professional career with Deloitte & Touche, LLP, where he served as a senior auditor. Mr. Gray has a Bachelor of Science degree in Accounting from Lehigh University and is a Certified Public Accountant in the State of New York.